Senti Biosciences Holdings, Inc. (SNTI)

Nasdaq: SNTI · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2021

Full chart Alerts Compare

Grade2.6

◀ Past 1.2● Present 2.1▶ Future 3.9

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Senti Biosciences Holdings, Inc.

Nine metrics read from its own filings, by tense

Headline grade

2.6/10

◀ Past1.225% of the headline

● Present2.135% of the headline

▶ Future3.940% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.2/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.6/10

Has it survived what it has been through?

6 warning events since 2021; the latest 2026-09-02.

weight 22% of this tense · 6th percentile among 159 sector filers · read for itself

From the record

Senti Biosciences Holdings, Inc.'s filings since 2021 show 6 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-09-02); a warning not to rely on past financial statements (8-K item 4.02, the latest 2021-12-10); an auditor change (8-K item 4.01, the latest 2022-06-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

1.4/10

What has it actually done, year after year?

-68.7% a year over 5 filed years; profitable in 0 of 5.

weight 45% of this tense · 14th percentile among 102 sector filers · read for its customers

From the record

Senti Biosciences Holdings, Inc.'s 5 filed years say what it did: revenue went from $2 million in fiscal 2021 to $22 thousand in fiscal 2025, down 68.7% a year; it rose in 1 of 3 years; the deepest fall was 100% from fiscal 2022 to fiscal 2024; net income was positive in 0 of 5 of those years (its annual reports).

What it rests on

revenue growth over the filed span-68.7%bottom 1% of its family
the share of years revenue rosebottom 16% of its family
the share of filed years with a profitbottom 31% of its family
the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

1.4/10

How has it treated the people who own it?

SI estimate 1.4/10, confidence 35 of 100 (one part).

weight 33% of this tense · 14th percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 14% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Senti Biosciences Holdings, Inc.'s shareholder treatment is put at 1.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 14% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.1/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

1.0/10

Is it financially healthy right now?

ROE -1099%: lost 1099¢ per shareholder dollar. Leverage 89%: owes 89¢ per asset dollar.

weight 45% of this tense · 10th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Senti Biosciences Holdings, Inc. lost about 1099 cents for every dollar of shareholders' money. Leverage: it owed about 89 cents per dollar of assets, and net share issuance: its share count grew 389.2% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 21% of its family
return on equitybottom 3% of its family
the share count against the year beforebottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

0.1/10

How strong is its position in its industry?

bottom 1% of 102 in its family; net margin -279263.6%.

weight 22% of this tense · 1st percentile among 102 sector filers · read for its customers

From the record

Senti Biosciences Holdings, Inc.'s standing among 102 graded names in its industry family: revenue of $22 thousand in fiscal 2025 ranks in the bottom 2% by size; a net margin of -279263.6% ranks in the bottom 1%; revenue growth of -81.1% a year over the last 3 filed years ranks in the bottom 1% (its annual reports).

What it rests on

revenue against the family$22,000bottom 2% of its family
net margin-279263.6%bottom 1% of its family
three-year revenue growth-81.1%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 130 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record of its people begins on 2022-06-15 (a listing, a merger or a first filing under the rules) and its chief executive have filed since then, so the record shows a floor of 4.4 years and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 130 members with one.
What the record cannot read: The record of its people begins on 2022-06-15 (a listing, a merger or a first filing under the rules) and its chief executive have filed since then, so the record shows a floor of 4.4 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 130 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Senti Biosciences Holdings, Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because the record of its people begins on 2022-06-15 (a listing, a merger or a first filing under the rules) and its chief executive have filed since then, so the record shows a floor of 4.4 years and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 130 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.9/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

5.1/10

How much room does it have to grow?

top 49% of 92 in its family for room to expand.

weight 33% of this tense · 51st percentile among 92 sector filers · read for itself

From the record

Senti Biosciences Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $16 million against no long-term debt tagged leaves 32.1% of its assets as net cash, top 46% of its family; cash from operations less capital spending is -198363.6% of revenue (bottom 1%); research spending of 170845.5% of revenue (top 1%) (its annual report).

What it rests on

cash less debt against assets32.1%top 46% of its family
cash from operations less capital spending against revenue-198363.6%bottom 1% of its family
research spending against revenue170845.5%top 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

3.8/10

What could actually drive growth from here?

bottom 38% of 100 in its family for growth drivers.

weight 45% of this tense · 38th percentile among 100 sector filers · read for its customers

From the record

Senti Biosciences Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -81.1% a year over the last three filed years against -68.7% over all 5, slowing (bottom 43% of its family); research spending grew 10.1% a year (top 32%); capital spending grew -83.2% a year (bottom 3%) (its annual reports). Senti Biosciences Holdings, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-12.4 points a yearbottom 43% of its family
three-year growth of research spending10.1%top 32% of its family
three-year growth of capital spending-83.2%bottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

2.1/10

Did its newest year beat what its own record pointed to?

bottom 21% of 72 in its family for expectations against reality.

weight 22% of this tense · 21st percentile among 72 sector filers · read for its shareholders

From the record

Senti Biosciences Holdings, Inc.'s newest year against its own record: net income of $61 million against a prior three-year average of $61 million (bottom 41%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 1%) (its annual reports).

What it rests on

net income against the prior three years' average-1%bottom 41% of its family
net margin against its prior averagedown more than 100 pointsbottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton SNTI · research, not advice